InspireMD Company Overview

CGuard TM Product Development InspireMD . US FDA Pre-IDE FDA submission for CGuard™ February 2017 • Formal FDA meeting held April 2017 . FDA 9 months of pre-clinical work required to file IDE application to begin a US clinical trial • Next generation CGuard TM - 5 French CGuard™ • • • Minimally invasive devices trending smaller for broader usage Advantageous in the Asia Pacific markets Transradial delivery (delivery from the wrist vs. femoral artery) gaining favor among interventionalists Evaluate synergistic opportunities to broaden the product portfolio and take advantage of the global distribution network 21

View entire presentation